Fms-like tyrosine kinase 3 (FLT3) is an important member of the class III receptor tyrosine
kinase (RTK) family, which is involved in the proliferation of hematopoietic cells and …

Prognosis in relapsed and refractory acute myeloid leukemia (R/R AML) patients is dismal,
with no satisfactory and standard salvage chemotherapy regimen. We performed a …

Bone marrow (BM) is a highly complex tissue that provides important regulatory signals to
orchestrate hematopoiesis. Resident and transient cells occupy and interact with some well …

Resistance to the hypomethylating agents (HMAs) 5-azacytidine (AZA) and 5-aza-2′-
deoxycytidine (DAC) represents a major obstacle in the treatment of elderly patients with …

Simple Summary AML is a genetically heterogeneous disease with a median age of
diagnosis between 60 and 70 years. Thus, many AML patients are not eligible for intensive …

Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative
therapy for FLT3 internal tandem duplication mutant (FLT3-ITD+) acute myeloid leukemia …

Acute myeloid leukemia (AML) is a heterogeneous malignancy affecting myeloid cells in the
bone marrow (BM) but can spread giving rise to impaired hematopoiesis. AML incidence …

To explore the characteristics and prognostic significance of genetic mutations in acute
myeloid leukemia (AML), we screened the gene mutation profile of 171 previously untreated …

Simple Summary Patients with acute myeloid leukemia (AML) may have a number of
different mutations. Those with mutations in the FLT3 gene have a higher risk of relapse and …

Pracinostat, a potent oral pan-histone deacetylase inhibitor with modest single-agent activity
in acute myeloid leukemia (AML), has shown synergistic antitumor activity when combined …